论文部分内容阅读
目的:分析探讨急性心肌梗塞心血管内科在临床中的治疗方法和相应的治疗效果。方法:选择2016年2月至2017年2月本院收治的130例急性心肌梗塞患者作为研究组,随机分为实验组和对照组,每组65例。对照组患者采用常规治疗方式,实验组患者在常规治疗的基础上采用尿激酶治疗,对两组患者的临床疗效进行对比。结果:对照组有治疗效果的患者为49例,治疗有效率为75.4%;实验组有治疗效果的患者为62例,有效率为95.4%,实验组患者的治疗效果明显优于对照组(P<0.05)。结论:将尿激酶治疗应用于急性心肌梗塞心血管内科的临床规范治疗中,可以有效改善患者的心脏功能,降低并发症的发病率,明显提高治疗效果。
Objective: To analyze and discuss the clinical treatment and the corresponding therapeutic effect of cardiovascular medicine in patients with acute myocardial infarction. Methods: A total of 130 acute myocardial infarction patients admitted to our hospital from February 2016 to February 2017 were selected as study group and randomly divided into experimental group and control group, with 65 cases in each group. The patients in the control group were treated by conventional therapy. The patients in the experimental group were treated with urokinase on the basis of routine treatment, and the clinical efficacy was compared between the two groups. Results: In the control group, there were 49 cases with therapeutic effect, the effective rate was 75.4%. In the experimental group, 62 cases were treated with effective rate of 95.4%. The experimental group had better therapeutic effect than the control group (P <0.05). Conclusion: The application of urokinase in the clinical normative treatment of acute myocardial infarction and cardiovascular medicine can effectively improve the cardiac function, reduce the incidence of complications and improve the therapeutic effect.